

Dana P Ascherman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3059463/dana-p-ascherman-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

2,058
citations

24
h-index

45
g-index

48
ext. papers

2,510
ext. citations

5.5
avg, IF

4.6
L-index

#	Paper	IF	Citations
44	Association of Agricultural, Occupational, and Military Inhalants With Autoantibodies and Disease Features in US Veterans With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 392-400	9.5	3
43	The impact of airborne endotoxin exposure on rheumatoid arthritis-related joint damage, autoantigen expression, autoimmunity, and lung disease. <i>International Immunopharmacology</i> , 2021 , 100, 108069	5.8	3
42	Risk Factors and Cancer Screening in Myositis. <i>Rheumatic Disease Clinics of North America</i> , 2020 , 46, 565-576	5.7	11
41	Comparative Profiling of Serum Protein Biomarkers in Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 409-419	9.5	15
40	Malondialdehyde-Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis-Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1483-1493	9.5	26
39	Safety and efficacy of intravenous bimagrumb in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Neurology</i> , 2019 , 18, 834-844	24.1	55
38	Severe mononeuritis multiplex after rituximab in IgM- κ monoclonal gammopathy. <i>Muscle and Nerve</i> , 2018 , 57, E115-E118	3.4	1
37	Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2018 , 21, 1398-1405	2.3	6
36	Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts. <i>Current Rheumatology Reports</i> , 2017 , 19, 79	4.9	26
35	Citrullinated Autoantigen Targets as Markers of Extra-Articular Disease in Rheumatoid Arthritis 2017 , 191-203		
34	Extensive Citrullination Promotes Immunogenicity of HSP90 through Protein Unfolding and Exposure of Cryptic Epitopes. <i>Journal of Immunology</i> , 2016 , 197, 1926-36	5.3	23
33	Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. <i>Rheumatology</i> , 2016 , 55, 1631-41	3.9	24
32	Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2016 , 2016, 2812980	0.8	10
31	Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases. <i>Biomolecular Concepts</i> , 2016 , 7, 133-43	3.7	15
30	Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome. <i>Current Rheumatology Reports</i> , 2015 , 17, 56	4.9	18
29	Reversal of New-Onset Type 1 Diabetes With an Agonistic TLR4/MD-2 Monoclonal Antibody. <i>Diabetes</i> , 2015 , 64, 3614-26	0.9	14
28	Required role of apoptotic myogenic precursors and toll-like receptor stimulation for the establishment of autoimmune myositis in experimental murine models. <i>Arthritis and Rheumatology</i> , 2015 , 67, 809-22	9.5	11

27	Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1403-12	10.2	100
26	Immuno-proteomics: Development of a novel reagent for separating antibodies from their target proteins. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015 , 1854, 592-600	4	7
25	Pulmonary complications of inflammatory myopathy. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 249-62	2.4	15
24	Biologic predictors of clinical improvement in rituximab-treated refractory myositis. <i>BMC Musculoskeletal Disorders</i> , 2015 , 16, 257	2.8	31
23	Biomarkers of rheumatoid arthritis-associated interstitial lung disease. <i>Arthritis and Rheumatology</i> , 2015 , 67, 28-38	9.5	62
22	Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms. <i>Revista De Investigacion Clinica</i> , 2015 , 67, 280-6	1.6	35
21	Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 655-63	2.2	9
20	Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 227-32	2.4	172
19	Anti-citrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses. <i>Clinical Immunology</i> , 2014 , 155, 60-70	9	25
18	Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 740-9	9.5	167
17	A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. <i>Chest</i> , 2014 , 145, 454-463	5.3	50
16	Pulmonary manifestations of polymyositis/dermatomyositis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014 , 35, 239-48	3.9	55
15	Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. <i>Chest</i> , 2014 , 146, 41-50	5.3	54
14	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. <i>Arthritis and Rheumatism</i> , 2013 , 65, 314-24		383
13	Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2013 , 65, 869-79		88
12	Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositis. <i>Journal of Immunology</i> , 2013 , 191, 1865-72	5.3	17
11	Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 406927		37
10	Animal models of inflammatory myopathy. <i>Current Rheumatology Reports</i> , 2012 , 14, 257-63	4.9	10

9	Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 479-87		36
8	Interstitial lung disease in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2010 , 12, 363-9	4.9	40
7	Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2183-92		93
6	Structural and thermodynamic approach to peptide immunogenicity. <i>PLoS Computational Biology</i> , 2008 , 4, e1000231	5	33
5	Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3125-31		155
4	Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. <i>Journal of Autoimmunity</i> , 2007 , 29, 174-86	15.5	67
3	The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. <i>Current Rheumatology Reports</i> , 2003 , 5, 425-30	4.9	27
2	Pulmonary complications of inflammatory myopathy. <i>Current Rheumatology Reports</i> , 2002 , 4, 409-14	4.9	6
1	Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis. <i>Journal of Immunology</i> , 2002 , 169, 7127-34	5.3	22